Department of Transplant and Endocrine Surgery, Nagoya Second Red Cross Hospital, 2-9, Myoken-cho, Showa-ku, Nagoya 4668650, Japan.
World J Surg. 2009 Nov;33(11):2335-42. doi: 10.1007/s00268-009-9943-3.
Secondary hyperparathyroidsm (2HPT) is a common complication in hemodialysis patients associated with morbidity and sometimes mortality. The majority of patients with 2HPT can be managed by medical treatment. However, medical treatment does not always provide control of parathyroid disorder. Some patients require surgical treatment, parathyroidectomy (PTx). Successful surgical treatment often results in dramatic drop of the parathyroid hormone (PTH) levels, relieves the patients from clinical symptoms, and reduces mortality. However, at present we do not have reliable evidences showing that PTx.
The published papers about medical and surgical treatment for 2HPT within the last 10 years were evaluated to acquire the evidence for the adequate surgical treatments for 2HPT.
Many retrospective, observation studies have confirmed that successful PTx can achieve a dramatic drop of PTH levels, relieve symptoms of 2HPT and reduce mortality. However, we do not have reliable evidence that PTx compared with placebo or active drugs, improves mortality or outcome with respect to cardiovascular symptoms, bone disease, or biochemical parameter. The indications for surgery may be strongly influenced by medical therapy, including treatment with calcimimetics, as well as by composition of the patients material and medical insurance system. There are many treatment of modalities in addition to PTx for dialysis patients with 2HPT. Moreover, we do not have clear evidence telling us which operative procedures is most appropriate for 2HPT, with respect to clinical effectiveness, mortality or risk for recurrence.
To acquire the evidence for the adequate medical and surgical treatment for 2HPT including operative procedures, randomized controlled prospective studies are requires.
继发性甲状旁腺功能亢进症(2HPT)是血液透析患者的常见并发症,与发病率有关,有时与死亡率有关。大多数 2HPT 患者可以通过药物治疗进行管理。然而,药物治疗并不总能控制甲状旁腺疾病。一些患者需要手术治疗,甲状旁腺切除术(PTx)。成功的手术治疗通常会导致甲状旁腺激素(PTH)水平急剧下降,缓解患者的临床症状,并降低死亡率。然而,目前我们没有可靠的证据表明 PTx 可以做到这一点。
评估了过去 10 年中关于 2HPT 药物和手术治疗的已发表论文,以获取有关 2HPT 充分手术治疗的证据。
许多回顾性观察研究证实,成功的 PTx 可以显著降低 PTH 水平,缓解 2HPT 的症状并降低死亡率。然而,我们没有可靠的证据表明与安慰剂或活性药物相比,PTx 可以改善死亡率或心血管症状、骨骼疾病或生化参数方面的预后。手术的适应证可能会受到药物治疗的强烈影响,包括使用钙敏感受体激动剂,以及患者的具体情况和医疗保险制度。除了 PTx 之外,还有许多治疗方法可用于透析患者的 2HPT。此外,我们没有明确的证据表明哪种手术程序最适合 2HPT,无论是在临床效果、死亡率还是复发风险方面。
需要开展随机对照前瞻性研究,以获取 2HPT 包括手术治疗在内的充分药物和手术治疗的证据。